# BeOne Medicines Ltd. American (ONC) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $358.26, market value $40.5 billion.

## Valuation
- **P/E (trailing): 64.1×** (5-yr avg 1599.0×, 3-yr avg 1599.0×). BeOne Medicines Ltd. American trades at 64.1× trailing earnings, well below its own five-year average of 1599.0×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 34.8×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.25**. A PEG of 0.25 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 6.6×**. Each dollar of revenue is priced at 6.6×.
- **Price / book: 7.8×**. The shares trade at 7.8× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 34.3×**. Enterprise value is 34.3× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 3.3%** (5-yr avg -0.4%). Free cash flow equals 3.3% of the market value, above its five-year average of -0.4%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 1.6%**. The inverse of the P/E: 1.6% of the price is earned each year.

## Profitability
- **Gross margin: 88.9%**. BeOne Medicines Ltd. American keeps 88.9% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 15.1%**. 15.1% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 5.4%**. 5.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 6.6%**. 6.6% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 87.6%**. Return on all capital, debt included, is 87.6%: comfortably above what that capital costs.
- **Return on assets: 8.0%**. Each dollar of assets produces 8.0% of profit.

## Growth
- **Revenue growth (1 yr): 40.2%** (3-yr 55.7%/yr, 5-yr 76.8%/yr). Revenue grew 40.2% over the last year, against 76.8% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 140.4%**. Earnings per share rose 140.4%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.23**. Debt is 0.23 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. BeOne Medicines Ltd. American holds more cash than debt.
- **Altman Z-score: 7.93**. A Z-score of 7.93 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. BeOne Medicines Ltd. American does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (28 analysts). 28 analysts cover BeOne Medicines Ltd. American; the consensus is strong_buy, with an average price target of $432.16 (+21% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 12.4%** (YTD 17.9%, 3-mo 32.6%). The shares are up 12.4% over twelve months including dividends.
- **From 52-week high: -7.0%** (41.1% above the low). Trading 7% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 0.70** (volatility 38%). Beta of 0.70 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ONC · Page: https://foliofundamentals.com/stocks/onc

Not investment advice.